REFERENCES

1. Guven-Maiorov E, Acuner-Ozbabacan SE, Keskin O, Gursoy A, Nussinov R. Structural pathways of cytokines may iluminate their roles in regulation of cancer development and immunotherapy. Cancers (Basel) 2014;6:663-83.

2. Ai W, Li H, Song N, Li L, Chen H. Optimal method to stimulate cytokine production and its use in immunotoxicity assessment. Int J Environ Res Public Health 2013;10:3834-42.

3. Sultani M, Stringer AM, Bowen JM, Gibson RJ. Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy induced gastrointestinal mucositis. Chemother Res Pract 2012;2012:490804.

4. Allavena P, Germano G. Marchesi F, Mantovani, A. Chemokines in cancer related inflammation. Exp Cell Res 2011;317:664-73.

5. Matei I, Matei L. Cytokine patterns and pathogenicity in autoimmune disease. Rom J Intern Med 2002;40:27-41.

6. Pasha HF, Radwan MI, Hagrass HA, Tantawy EA, Emara MH. Cytokines genes polymorphisms in chronic hepatitis C: impact on susceptibility to infection and response to therapy. Cytokine 2013;61:478-84.

7. Cohen MC, Cohen S. Cytokine function: a study in biologic diversity. Am J Clin Pathol 1996;105:589-98.

8. Ikram N, Hassan K, Tufail S. Cytokines. Int J Pathol 2004;2:47-58.

9. SekIyama KD, Yoshiba M, Thomson AW. Circulating proinflammatory cytokines (IL-ll3, TNF-a, and IL-6) and IL-1 receptor antagonist (IL-lRa) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol 1994;98:71-7.

10. Oppenheim JJ. Cytokines: past, present, and future. Int J Hematol 2001;74:3-8.

11. Slifka MK, Whitton JL. Clinical implication of dysregulated cytokine production. J Mol Med (Berl) 2000;78:74-80.

12. Angkasekwinai P, Dong C. TH17 Cytokines: Characteristics, Regulation, and Biological Function. In: Jiang S, editor. TH17 Cells in Health and Disease. Berlin: Springer Science+Business Media LLC; 2011 .

13. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 2006;43:S54-62.

14. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998;16:27-55.

15. Symons JA, Young PR, Duff GW. Soluble type II interleukin I (IL-1) receptor binds and blocks processing of IL-1β precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci U S A 1995;92:1714-8.

16. Ceni E, Mello T, Galli A. Pathogenesis of alcoholic liver disease: Role of oxidative metabolism. World J Gastroenterol 2014;20:17756-72.

17. McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease: IV- Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004;287:G497-502.

18. Kitazawa T, Nakatani Y, Fujimoto M, Tamura N, Uemura M, Fukui H. The production of tumor necrosis factor-a by macrophages in rats with acute alcohol loading. Alcohol Clin Exp Res 2003;27:S72-5.

19. Tsujimoto T, Kuriyama S, Yamazaki M, Nakatani Y, Okuda H, Yoshiji H, Fukui H. Augmented hepatocellular carcinoma progression and depressed Kupffer cell activity in rat cirrhotic livers. Int J Oncol 2001;18:41-7.

20. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int 2006;26:1175-86.

21. Diehl AM. Recent events in alcoholic liver disease: V. Effects of ethanol on liver regeneration. Am J Physiol Gastrointest Liver Physiol 2005;288:G1-6.

22. Aldred ND, Nagy LE. Ethanol dissociates hormone stimulated cAMP production from inhibition of TNF-a production in rat Kupffer cells. Am J Physiol 1999;276:G98-106.

23. Hill DB, Marsano L, Cohen D, Allen J, Shedlofsky S, McClain CJ. Increased plasma interleukin-6 concentrations in alcoholic hepatitis. J Lab Clin Med 1992;119:547-52.

24. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-48.

25. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, Ludwiczek O, Shawcross D, Zoller H, Alisa A, Mookerjee RP, Graziadei I, Datz C, Trauner M, Schuppan D, Obrist P, Vogel W, Williams R. Anti-tumor necrosis factor alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003;38:419-25.

26. Hong F, Kim WH, Tian Z, Jaruga B, Ishac E, Shen X, Gao B. Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2 and Bcl-xL proteins. Oncogene 2002;21:32-43.

27. Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol 2005;2:92-100.

28. Kasztelan-Szczerbińska B, Surdacka A, Celiński K, Roliński J, Zwolak A, Miącz S, and Szczerbiński M. Prognostic significance of the systemic inflammatory and immune balance in alcoholic liver disease with a focus on gender-related differences. PLoS One 2015;10:e0128347.

29. Zhang X, Tachibana S, Wang H, Hisada M, Williams GM, Gao B, Sun Z. Interleukin-6 is an important mediator for mitochondrial DNA repair after alcoholic liver injury in mice. Hepatology 2010;52:2137-47.

30. Lemmers A, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Devière J. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009;49:646-57.

31. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, Barrieau M, Min SY, Kurt-Jones EA, Szabo G. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 2012;122:3476-89.

32. Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: the diagnosis and management. World J Hepatol 2015;7:846-58.

33. Lalor PF, Faint J, Aarbodem Y, Hubscher SG, Adams DH. The role of cytokines and chemokines in the development of steatohepatitis. Semin Liver Dis 2007;27:173-93.

34. Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M. Prolonged activation of jun and collagenase genes by tumor necrosis factor-alpha. Nature 1989;337:661-3.

35. Olteanu S, Kandel-Kfir M, Shaish A, Almog T, Shemesh S, Barshack I, Apte RN, Harats D, Kamari Y. Lack of interleukin-1α in Kupffer cells attenuates liver inflammation and expression of inflammatory cytokines in hypercholesterolaemic mice. Dig Liver Dis 2014;46:433-9.

36. Ikejima K, Okumura K, Kon K, Takei Y, Sato N. Role of adipocytokines in hepatic fibrogenesis. J Gastroenterol Hepatol 2007:S87-92.

37. Rajala MW, Scherer PE. Minireview: The adipocyte-at the cross roads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003;144:3765-73.

38. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, Richelsen B. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003;285:E527-33.

39. Hukshorn CJ, Lindeman JH, Toet KH, Saris WH, Eilers PH, Westerterp-Plantenga MS, Kooistra T. Leptin and the proinflammatory state associated with human obesity. J Clin Endocrinol Metab 2004;89:1773-8.

40. You T, Berman DM, Rayan S, Nicklas BJ. Effect of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese post-menopausal women. J Clin Endocrinol Metab 2004;89:1739-46.

41. Pravo PE, Morse S, Borne DM, Aguilar EA, Reisin E. Leptin and hypertension. Vasc Health Risk Manag 2006;2:163-9.

42. Popper H. Cholestasis: the future of a past and present riddle. Hepatology 1981;1:187-91.

43. Keith G, Tolman MD, Rej R. Liver function. In: Burtis CA, Ashwood ER, Tietz NW, editors. Tietz Textobook of Clinical Chemistry, Volume 3, Chapter 33. Philadelphia, PA: W.B. Saunders; 1999.

44. Spirlì C, Fabris L, Duner E, Fiorotto R, Ballardini G, Roskams T, Larusso NF, Sonzogni A, Okolicsanyi L, Strazzabosco M. Cytokine-stimulated nitric oxide production inhibits adenyl cyclase and cAMP-dependent secretion in cholangiocytes. Gastroenterology 2003;124:737-53.

45. Ahmed HH, Mannaa F. Curcumin as an effective agent against ethinylestradiol-induced hepatocellular cholestaris. Egypt J Med Lab Sci 2004;13:1-16.

46. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanism of hepatotoxicity. Toxicol Sci 2002;65:166-76.

47. Sträter J, Möller P. Pathogenesis of primary biliary cirrhosis: CD 95-induced apoptosis at last? Eur J Gastroenterol Hepatol 1998;10:539-41.

48. Fox ES, Kim JC, Tracy TF. NF-Kappa β activation and modulation in hepatic macrophages during cholestatic injury. J Surg Res 1997;72:129-34.

49. Ferrari C, Valli A, Galati L, Penna A, Scaccaglia P, Giuberti T, Schianchi C, Missale G, Marin MG, Fiaccadori F. T-cell response to structural and non-structural hepatitis C virus antigen in persistent and self limited hepatitis C virus infection. Hepatology 1994;19:286-95.

50. Abd-Elghaffar Y, Fouad HH, Eid A. Effect of interferon-α therapy on oxidative stress in hepatitis C virus infection. Arab J Lab Med 1999;25:345-54.

51. Lee J, Tian Y, Chan ST, Kim JY, Cho C, Ou JH. TNF-α induced by hepatitis C virus via TLR7 and TLR8 in hepatocytes supports interferon signaling via an autocrine mechanism. PLoS Pathog 2015;11:e1004937.

52. Zalata AA, Morsy HK, Atwa AA, El-bendary MM. Relationship between S-Adenosylmethionine, S-Adenosylhomocysteine, Tumor necrosis factor-α, reduced glutathione and nitrite in liver cirrhosis. Egypt J Biochem Molecular boil 2007;25:362-82.

53. Nessim I, Abu-Zikri N, Moussa M, Hafez T, Hazem A, Reda M, Abdel-Hadi A, Edward N, El-Ghafir W. Implication of tumor-necrosis factor alpha (TNF-α): Interleukin-1 Beta (IL1-β) and intercellular adhesion molecule-1 (ICAM-1) in warm hepatic ischaemia-reperfusion injury: Effect of intraportal infusion of prostaglandin E-1. Egypt J Lab Med 2002;14:243-74.

54. Martínez-Esparza M, Tristán-Manzano M, Ruiz-Alcaraz AJ, García-Pe-arrubia P. Inflammatory status in human hepatic cirrhosis. World J Gastroenterol 2015;21:11522-41.

55. Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL, Houghton M, Walker BD. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995;96:2311-21.

56. Lechmann M, Woitas RP, Langhans B, Kaiser R, Ihlenfeldt HG, Jung G, Sauerbruch T, Spengler U. Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. J Hepatol 1999;31:971-8.

57. Cribier B, Schmitt C, Rey D, Landg JM, Kirn A, Stoll-Keller F. Production of cytokines in patients infected by hepatitis C virus. J Med Virol 1998;55:89-91.

58. McGuinness PH, Painter D, Davies S, McCaughan GW. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 2000;46:260-9.

59. Gonzalez-Flecha B, Reides C, Cutrin JC, Llesuy SF, Boveris A. Oxidative stress produced by suprahepatic occlusion and reperfusion. Hepatology 1993;18:881-9.

60. Goossens V, Grooten J, Devos K, Fiers W. Direct evidence for tumor necrosis factor induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Nat Acad USA 1995;92:8115-9.

61. Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC Jr, Balart LA, Ortego TJ, Payne J, Dienstag JL, Gibas A, Jacobson IM, Tamburro CH, Carey W, O'Brien C, Sampliner R, Van Thiel DH, Feit D, Albrecht J, Meschievitz C, Sanghvi B, Vaughan RD; The Hepatitis Interventional Therapy Group. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study in chronic hepatitis B. Gastroenterology 1993;104:595-603.

62. Mandelker L. Oxidative stress, free radicals, and cellular damage In: Mandelker L, Vajdovich P, editors. Studied on Veterinary Medicine. Berlin: Springer Science+Business Media LLC; 2011. pp. 1-18.

63. Jia B, Guo M, Li G, Yu D, Zhang X, Lan K, Deng Q. Hepatitis B virus core protein sensitizes hepatocytes to tumor necrosis factor-induced apoptosis by suppression of the phosphorylation of mitogen-activated protein kinase Kinase 7. J Virol 2015;89:2041-51.

64. Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000;74:4165-73.

65. Lok AS. Hepatitis B infection: pathogenesis and management. J Hepatol 2000;32:89-97.

66. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997;71:3236-43.

67. Li Z, Chen L, Liu Q. Activation of CXCL-8 Transcription by hepatitis E virus ORF-1 via AP-1. Mediators Inflamm 2015;2015:495370.

68. Kumar A, Devi SG, Kar P, Agarwal S, Husain SA, Gupta RK, Sharma S. Association of cytokines in hepatitis E with pregnancy outcome. Cytokine 2014;65:95-104.

69. Iarotski LS, Davis A. The schistosomiasis problem in the world: results of a WHO questionnaire survey. Bull World Health Organ 1981;59:115-27.

70. Duan Y, Gu X, Zhu D, Sun W, Chen J, Feng J, Song K, Xu F, He X, He X. Schistosoma japonicum soluble egg antigens induce apoptosis and inhibit activation of hepatic stellate cells: a possible molecular mechanism. Int J Parasitol 2014;44:217-24.

71. Huang J, Tao R, Li L, Ma K, Xu L, Ai G, Fan X, Jiao Y, Ning Q. Involvement of heat shock protein 47 in Schistosoma japonicum-induced hepatic fibrosis in mice. Int J Parasitol 2014;44:23-35.

72. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004;4:583-94.

73. Silveira-Lemos D, Teixeira-Carvalho A, Martins-Filho OA, Oliveira LFA, Costa-Silva MF, Matoso LF, de Souza LJ, Gazzinelli A, Correˆa-Oliveira R. Eosinophil activation status, cytokines and liver fibrosis in Schistosoma mansoni infected patients. Acta Trop 2008;108:150-9.

74. Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, Wynn TA. Immunopathology of schistosomiasis. Immunol Cell Biol 2007;85:148-54.

75. Mwatha JK, Kimani G, Kamau T, Mbugua GG, Ouma JH, Mumo J, Fulford AJ, Jones FM, Butterworth AE, Roberts MB, Dunne DW. High levels of TNF, soluble TNF receptors, soluble ICAM-1, and IFN-gamma, but low levels of IL-5, are associated with hepatosplenic disease in human Schistosomiasis mansoni. J Immunol 1998;160:1992-9.

76. Sombetzki M, Fuchs CD, Fickert P, ضsterreicher CH, Mueller M, Claudel T, Loebermann M, Engelmann R, Langner C, Sahin E, Schwinge D, Guenther ND, Schramm C, Mueller-Hilke B, Reisinger EC, Trauner M. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. J Hepatol 2015;62:871-8.

77. Hou X, Yu F, Man S, Huang D, Zhang Y, Liu M, Ren C, Shen J. Polyinosinic-polycytidylic acid attenuates hepatic fibrosis in C57BL/6 mice with Schistosoma japonicum infection. Acta Trop 2012;121:99-104.

78. Ferri S, Longhi MS, De Molo C, Lalanne C, Muratori P, Granito A, Hussain MJ, Ma Y, Lenzi M, Mieli-Vergani G, Bianchi FB, Vergani D, Muratori L. A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis. Hepatology 2010;52:999-1007.

79. Holder BS, Grant CR, Liberal R, Maa Y, Heneghan MA, Mieli-Vergani G, Vergani D, Longhi MS. Retinoic acid stabilizes antigen-specific regulatory T-cell function in autoimmune hepatitis type 2. J Autoimmun 2014;53:26-32.

80. Cherٌavsky AC, Paladino N, Rubio AE, De Biasio MB, Periolo N, Cuarterolo M, Goٌi J, Galoppo C, Caٌero-Velasco MC, Muٌoz AE, Fainboim H, Fainboim L. Simultaneous expression of Thl cytokines and IL-4 confers severe characteristics to type I autoimmune hepatitis in children. Hum Immunol 2004;65:683-91.

81. Moritoki Y, Lian ZX, Ohsugi Y, Ueno Y, Gershwin ME. B cells and autoimmune liver diseases. Autoimmun Rev 2006;5:449-57.

82. Solari NEF, Galoppo C, Cuarterolo M, Goٌi J, Fernلndez-Salazar L, Arranz LE, Garrote J, Cherٌavsky AC. The simultaneous high expression of Vα24, IFN-γ and FoxP3 characterizes the liver of children with type I autoimmune hepatitis. Clin Immunol 2010;137:396-405.

83. Gresner AM. The up-and-down of hepatic stellate cells in tissue injury: apoptosis restores cellular homeostasis. Gastroenterology 2001;120:1285-8.

84. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, Arthur MJ. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102:538-49.

85. Gressner AM. Liver fibrosis: perspectives in pathobiochemical research and clinical outlook. Eur J Clin Chem Clin Biochem 1991;29:293-311.

86. Svegliati Baroni G, D'Ambrosio L, Ferretti G, Casini A, Di Sario A, Salzano R, Ridolfi F, Saccomanno S, Jezequel AM, Benedetti A. Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology 1998;27:720-6.

87. Thirunavukkarasu C, Watkins S, Harvey SAK, Gandhi CR. Superoxide-induced apoptosis of activated rat hepatic stellate cells. J Hepatol 2004;41:567-75.

88. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18.

89. Yee LJ, Tang J, Herrera J, Kaslow RA, van Leeuwen DJ. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000;1:386-90.

90. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003;37:493-503.

91. Han YP, Zhou L, Wang J, Xiong S, Garner WL, French SW, Tsukamoto H. Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem 2004;279:4820-8.

92. Marek B, Kajdaniuk D, Mazurek U, Janczewska-Kazek E, Kos-Kudla B, Strzalka B, Fila A, Niedziolka D, Beniowski M, Ostrowska Z, Borgiel-Marek H, Kajdaniuk J, Sieminska L, Nowak M, Wilczok T, Pakula D, Filipczyk P. TGF-beta l mRNA expression in liver biopsy specimens and TGF-beta l serum levels in patients with chronic hepatitis C before and after antiviral therapy. J Clin Pharm Ther 2005;30:271-7.

93. Nelson DR, Lauwers GY, Lau Y J, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000;118:655-60.

94. Jacobson Brown PM, Neuman MG. Immunopathogenesis of hepatitis C viral infection: Thl/Th2 responses and the role of cytokines. Clin Biochem 2001;34:167-71.

95. Goyal A, Kazim SN, Sakhuja P, Malhotra V, Arora N, Sarin SK. Association of TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus. J Med Virol 2004;72:60-5.

96. Cacciarelli TV, Martintez OM, Gish RG, Villarnueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre-and posttreatment with interferon alfa. Hepatology 1996;24:6-9.

97. Lu DH, Guo XY, Qin SY, Luo W, Huang XL, Chen M, Wang JX, Ma SJ, Yang XW, Jiang HX. Interleukin-22 ameliorates liver fibrogenesis by attenuating hepatic stellate cell activation and downregulating the levels of inflammatory cytokines. World J Gastroenterol 2015;21:1531-45.

98. Hsia CY, Huo TI, Chiang SY, Lu MF, Sun CL, Wu JC, Lee PC, Chi CW, Lui WY, Lee SD. Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers of hepatocellular carcinoma. Eur J Surg Oncol 2007;33:208-12.

99. El-Medany OM, Abdel Wahab KS, Abu Shady EA, Gad El-Hak N. Chronic liver disease and hepatitis C virus in Egyptian patients. Hepatogastroenterology 1999;46:1895-903.

100. Stoll-Keller F, Schvoerer E, Thumann C, Navas MC, Aubertin AM. Immunomodulating effect of HCV during the development of chronic hepatitis C: toward new therapeutic approaches. Bull Acad Natl Med 2003;187:1147-60; discussion 1160-1. (in French)

101. Elrefaei M, El-Sheikh N, Kamal K, Cao H. HCV-specific CD27- CD28- memory T cells are depleted in hepatitis C virus and Schistosoma mansoni co-infection. Immunology 2003;110:513-8.

102. Marotta F, Vangieri B, Cecere A, Gattoni A. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Clin Ter 2004;155:187-99.

103. Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel) 2011;3:3856-93.

104. Fainboim L, Chernavsky A, Paladino N, Flores AC, Arruvito L. Cytokines and chronic liver disease. Cytokine Growth Factor Rev 2007;18:143-57.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/